Baird Maintains an 'Outperform' on Human Genome Sciences (HGSI); Early Read on Benlysta Launch Very Encouraging

Baird maintains an 'Outperform' on Human Genome Sciences (NASDAQ: HGSI), PT $32.

Baird analyst says, "Incrementally positive on HGSI based on results of BioTrends’ most recent rheumatologist survey (fielded ~6-weeks post-launch) showing high favorability ratings, breadth-of-use and – most importantly – above-consensus near-term projected use for Benlysta. While the inevitable managed care and logistical issues are also evident, and this is still very much early days, we are very encouraged by this feedback and remain buyers for what we think will be a better-than-expected launch."

"Increasingly confident in better-than-expected launch. We model FY11 US
revenue of $103M (consensus $75M). With this feedback, we continue to think
consensus may be too low. Aggressive buyers."

For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.

Shares of Human Genome Sciences closed at $25.00 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Deutsche Bank Downgrades Workday (WDAY) to Hold
• Deutsche Bank Downgrades SentinelOne Inc (S) to Hold on Valuation
• NeuroPace (NPCE) Reiterated at Overweight by Cantor Fitzgerald on Commercial Momentum